← Back to Screener
Mineralys Therapeutics, Inc. Common Stock (MLYS)
Price$31.11
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-40.70%
Price vs S&P 500 (4W)2.68%
VGM Score65.26
Market Capitalization$2.60B
All Metrics
Book Value / Share (Quarterly)$7.74
P/TBV (Annual)2.42x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.65
Price vs S&P 500 (YTD)-24.13%
EPS (TTM)$-2.06
10-Day Avg Trading Volume1.36M
EPS Excl Extra (TTM)$-2.06
EPS (Annual)$-2.29
ROI (Annual)-23.91%
Cash / Share (Quarterly)$7.84
ROA (Last FY)-23.37%
EBITD / Share (TTM)$-2.29
ROE (5Y Avg)-98.88%
Cash Flow / Share (Annual)$-1.75
P/B Ratio4.07x
P/B Ratio (Quarterly)3.50x
Net Income / Employee (Annual)$-2,034,900
Net Interest Coverage (TTM)-27.37x
ROA (TTM)-26.98%
EPS Incl Extra (Annual)$-2.29
Current Ratio (Annual)43.76x
Quick Ratio (Quarterly)43.90x
3-Month Avg Trading Volume1.20M
52-Week Price Return101.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.42
52-Week High$47.65
EPS Excl Extra (Annual)$-2.29
26-Week Price Return-24.77%
Quick Ratio (Annual)43.45x
13-Week Price Return8.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)44.33x
Enterprise Value$2.49B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.05
3-Month Return Std Dev65.38%
Net Income / Employee (TTM)$-1,997,100
ROE (Last FY)-23.91%
EPS Basic Excl Extra (Annual)$-2.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.06
ROI (TTM)-27.92%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.87
Price vs S&P 500 (52W)72.94%
Year-to-Date Return-13.20%
5-Day Price Return5.53%
EPS Normalized (Annual)$-2.29
ROA (5Y Avg)-67.76%
Month-to-Date Return18.20%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-2.52
ROI (5Y Avg)-98.88%
EPS Basic Excl Extra (TTM)$-2.06
P/TBV (Quarterly)0.98x
P/B Ratio (Annual)4.44x
Book Value / Share (Annual)$7.93
Price vs S&P 500 (13W)-1.24%
Beta0.49x
Revenue / Share (TTM)$0.00
ROE (TTM)-27.92%
52-Week Low$12.59
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.47est. -0.47
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.20
4.20
4.19
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MLYSMineralys Therapeutics, Inc. Common Stock | — | — | B | $31.11 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a selective aldosterone synthase inhibitor for treatment-resistant hypertension. The orally administered drug targets abnormally elevated aldosterone levels in patients who have not responded to multiple existing antihypertensive therapies.